Compare Neurocrine Biosciences Inc (NBIX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Clear Secure Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Clear Secure Inc trades at $43.54 (market cap $4.44B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.2× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Clear Secure Inc for 19 Days on average.
| NBIX | YOU | |
|---|---|---|
Market Cap | $14.36B | $4.44B |
Volume | 1,237,180 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $185.50 | $62.36 |
52-Week Low | $123.10 | $29.61 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $14.37B | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability metrics including 66.7% gross margin and 90.3% ROE. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives.
The stock offers 44% upside to the $61.40 consensus target with analyst sentiment divided equally between Buy and Hold. Key risks include competitive pressures and execution of expansion plans. Strong cash flow generation and accelerating membership growth support the bullish case, though valuation multiples remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
